Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:8/28/2008

SAN FRANCISCO, Aug. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:

-- BioCentury's NewsMakers in the Biotech Industry on Thursday, September 4, at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center

-- 2008 UBS Global Life Sciences Conference on Wednesday, September 24, at 4:30 p.m. Eastern Time at the Grand Hyatt New York

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Senior Management Promotions
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
8. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 Immunovaccine Inc. (“Immunovaccine” or the ... fraudulent press release disseminated this morning by PR Web, ... This press release states that Immunovaccine has entered into ... press release did not originate from Immunovaccine and there ... press release. Please note that all official statements ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
(Date:2/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has ... Trypsin" report to their offering. , ... comprehensive data on Trypsin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:2/27/2015)... COLUMBIA, Md. (PRWEB) February 27, 2015 ... Unified Chromatography system (Nexera UC) can sequentially analyze ... chromatographic separation combined with high-sensitivity detection of targets ... system is designed to fulfill the measurement requirements ... pesticides in food products, drug delivery and search ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... Stevens Institute of Technology and NACE International, ... Section, will host the Winter 2007 Corrosion Symposium: ... Charles V. Schaefer, Jr. School of Engineering & ... Keith Sheppard, a professor materials engineering, will welcome ...
... offers innovative casting, splinting and bracing technology, ... Enova Medical Technologies,Inc. of St. Paul, Minn., ... are pleased to announce the launch of ... develop and commercialize innovative orthopedic,support devices. ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... received notification from the NASDAQ Listing,Qualifications Department that ... million,market value of listed securities requirement for continued ... NASDAQ Marketplace Rule 4310(c)(3)(B).,In accordance with Marketplace Rule ...
Cached Biology Technology:Enova Medical Launches Exos Corporation 2Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq 2
(Date:2/19/2015)... DUBLIN , Feb .19, 2015 Research ... announced the addition of the "Military Electro-Optical ... by Sensor Technology, by Platform - Forecast to ... The military electro-optical/infrared systems market is expected ... a CAGR of 7.71%. This report ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... extra genes gave fish on separate continents the ability ... of Texas at Austin. , Dr. Harold Zakon and ... the National Academy of Sciences, show that African and ... by modifying sodium channel proteins typically used in muscle ...
... a possible hibernation hormone in the brain may unlock ... the April 7, 2006 issue of Cell. Hibernation allows ... state of suspended animation--under the harshest of winter conditions. ... hormone would represent the first essential brain signal governing ...
... L-arginine following a heart attack does not improve certain ... an increased risk of death, according to a study ... is a widely available dietary supplement and is publicized ... failure and sexual dysfunction, according to background information in ...
Cached Biology News:Convergent evolution of molecules in electric fish 2Possible brain hormone may unlock mystery of hibernation 2Possible brain hormone may unlock mystery of hibernation 3Use of amino acid supplement following a heart attack provides no benefit, may be harmful 2
LAB/Probe Mouse-Rabbit DAB Kit...
Novagen's Calf Liver tRNA is qualified for use in reticulocyte lysates for in vitro translation, and is the same supplement used in the Red Nova Lysate ....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Biology Products: